title: Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals.
abstract: Symptoms and quality of life were assessed among human immunodeficiency virus (HIV)-infected individuals initiating their first course of antiretroviral therapy. Symptoms, which were mostly mild or moderate, were common in the first year and significantly affected the patients' quality of life. Quality of life was inversely related to the number of symptoms and in the change in the number of symptoms from baseline.
authors.affiliation: Division of Infectious Diseases, Harlem Hospital Center, New York, New York, USA. sbm20@columbia.edu
authors.forename: Sharon B
authors.initials: SB
authors.lastname: Mannheimer
authors.forename: Nicholas
authors.initials: N
authors.lastname: Wold
authors.forename: Edward M
authors.initials: EM
authors.lastname: Gardner
authors.forename: Edward E
authors.initials: EE
authors.lastname: Telzak
authors.forename: Katherine
authors.initials: K
authors.lastname: Huppler Hullsiek
authors.forename: Margaret
authors.initials: M
authors.lastname: Chesney
authors.forename: Albert W
authors.initials: AW
authors.lastname: Wu
authors.forename: Rodger D
authors.initials: RD
authors.lastname: MacArthur
authors.forename: John
authors.initials: J
authors.lastname: Matts
authors.forename: Gerald
authors.initials: G
authors.lastname: Friedland
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors